ADC Therapeutics SA Net Profit Margin 2019-2023 | ADCT

ADC Therapeutics SA net profit margin from 2019 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue.
ADC Therapeutics SA Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2023-03-31 $0.18B $-0.20B -108.79%
2022-12-31 $0.21B $-0.16B -74.64%
2022-09-30 $0.16B $-0.17B -106.41%
2022-06-30 $0.09B $-0.19B -201.08%
2022-03-31 $0.08B $-0.20B -245.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.192B $0.210B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $137.206B 8.38
GSK (GSK) United Kingdom $71.088B 9.92
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
QIAGEN (QGEN) Netherlands $10.347B 21.85
Ginkgo Bioworks Holdings (DNA) United States $3.670B 0.00
Arcus Biosciences (RCUS) United States $1.582B 0.00
Biohaven (BHVN) United States $1.578B 0.00
Emergent Biosolutions (EBS) United States $0.423B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.016B 0.00